Login / Signup

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review.

Yiru ZhangQigu YaoYong PanXinru FangHaoying XuTingxiao ZhaoGuangqi ZhuTianan JiangShibo LiHongcui Cao
Published in: Cancers (2023)
Treatment with PD-1/PD-L1 inhibitors in combination with other antitumor therapies improve patients' ORR, DCR, and PFS compared to anti-PD-1/PD-L1. However, it is regrettable that there is no benefit to OS and an increased risk of AEs in combinatorial therapies.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • dna damage
  • prognostic factors
  • cell cycle
  • oxidative stress